论文部分内容阅读
作者前瞻性评估了126例大剂量化疗(HDC)并自体外周血干细胞移植(APBSCT)后给广谱抗菌方案的疗效。126例中男12例,女114例,中位年龄41(18～59)岁。乳腺癌104例,卵巢癌、胚细胞瘤及淋巴癌各6例,其他肿瘤4例。动员方案:单用G-CkSF78例(10μg/kg·d)或化疗后加用G-CSF48例。当CD34~+细胞≥2×10~6/kg时进行干细胞采集。所有患者在动员前给锁骨下静脉置双腔导管,HDC前无活动性感染。HDC方案:(1)乳腺癌及卵巢癌用CTX(1.5g/m~2d-7～-4)+卡铂(200mg/m~2d-7～-4)+噻替哌(125mg/m~2d-7～-4);(2)淋巴瘤用BCNU(300mg/m~2d-6)+Vp16(100mg/m~2Q12Hd-5
The authors prospectively evaluated the efficacy of 126 high-dose chemotherapy (HDC) and broad-spectrum antibacterial regimens after autologous peripheral blood stem cell transplantation (APBSCT). In 126 cases, there were 12 males and 114 females, with a median age of 41 (18-59) years. There were 104 cases of breast cancer, 6 cases of ovarian cancer, blastoma and lymphoma, and 4 cases of other tumors. Mobilization program: 78 cases of G-CkSF alone (10μg/kg·d) or chemotherapy plus G-CSF after 48 cases. Stem cell collection was performed when CD34~+ cells ≥ 2 x 10~6/kg. All patients had dual-lumen catheters placed in the subclavian vein prior to mobilization and there was no active infection before HDC. HDC program: (1) CTX for breast and ovarian cancer (1.5g/m~2d-7~-4)+carboplatin (200mg/m~2d-7~-4)+thiotepa (125mg/m~ 2d-7～-4); (2) BCNU (300mg/m~2d-6) + Vp16 for lymphoma (100mg/m~2Q12Hd-5)